Venus Concept Inc Stock Price, News & Analysis

Venus Concept (NASDAQ: VERO) has closed a registered direct offering priced at-the-market, raising $1.15 million through the sale of 434,720 shares at $2.65 per share. The company also issued unregistered short-term warrants in a concurrent private placement for up to 869,440 shares at $2.65 per share, which could generate an additional $2.3 million if fully exercised. The warrants are immediately exercisable and expire in 18 months. H.C. Wainwright & Co. served as the exclusive placement agent. The proceeds will be used for general corporate purposes. The offering includes registered common stock under Form S-3 and unregistered warrants issued under Section 4(a)(2) of the Securities Act.

Venus Concept (NASDAQ: VERO) has announced a registered direct offering of 434,720 shares at $2.65 per share, priced at-the-market under Nasdaq rules, expected to raise $1.15 million in gross proceeds. Additionally, the company will issue unregistered short-term warrants in a concurrent private placement to purchase up to 869,440 shares at $2.65 per share, potentially generating an additional $2.3 million if fully exercised. The warrants will be immediately exercisable and expire after 18 months. H.C. Wainwright & Co. is serving as the exclusive placement agent, with the offering expected to close around June 9, 2025. The company plans to use the proceeds for general corporate purposes.

Venus Concept (NASDAQ: VERO) has announced a definitive agreement to sell its Venus Hair business to Meta Healthcare Group for $20 million in cash. The transaction includes the sale of the company's hair restoration portfolio, including ARTAS and NeoGraft technologies, along with related equipment, services, and intellectual property. The deal also includes the transfer of Venus Concept's San Jose manufacturing facility. The Venus Hair business generated revenue of $12.5 million in FY2024 but used $6.7 million in cash from operations. The transaction is expected to close in Q3 2025. This strategic move aims to strengthen Venus Concept's focus on its global medical aesthetics business, potentially improving revenue growth, reducing operating expenses, and accelerating the path to profitability. Meta Healthcare Group will receive a comprehensive hair restoration portfolio and manufacturing capabilities, while Venus Concept will retain a perpetual, royalty-free, worldwide license for certain transferred patents.

Venus Concept (NASDAQ: VERO) reported challenging Q1 2025 financial results with total revenue of $13.6 million, down 22% year-over-year. The company posted a GAAP net loss of $12.4 million, compared to $9.8 million last year, while Adjusted EBITDA loss widened to $8.3 million from $5.1 million. Operating expenses decreased 6% year-over-year to $18.3 million, reflecting cost containment efforts. Post-quarter, Venus Concept strengthened its balance sheet through debt restructuring with Madryn Asset Management and two equity offerings raising approximately $2.67 million in gross proceeds. The company's cash position stood at $3.2 million with total debt of $35.5 million as of March 31, 2025. Due to ongoing strategic evaluations and market uncertainties, Venus Concept is not providing full-year 2025 guidance.

Venus Concept (NASDAQ: VERO) has successfully completed its previously announced registered direct offerings, raising total gross proceeds of approximately $2.7 million. The latest offering closed with the sale of 386,700 shares of common stock at $4.06 per share, generating approximately $1.57 million. This follows a previous offering that closed on April 10, 2025, which raised approximately $1.15 million.

The offerings were conducted as registered direct offerings priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. serving as the exclusive placement agent. The medical aesthetic technology company plans to use the net proceeds for general corporate purposes. The shares were offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on November 1, 2024.

Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has announced a registered direct offering of 386,700 shares of common stock priced at $4.06 per share. The offering, priced at-the-market under Nasdaq rules, is expected to generate gross proceeds of approximately $1.5 million before deducting placement agent fees and expenses.

The closing is anticipated around April 14, 2025, subject to customary conditions. H.C. Wainwright & Co. serves as the exclusive placement agent. The company plans to use the net proceeds for general corporate purposes. The offering is made pursuant to an effective S-3 shelf registration statement previously filed with the SEC.

Venus Concept (NASDAQ: VERO) has successfully closed its previously announced registered direct offering, raising approximately $1.1 million in gross proceeds through the sale of 328,573 shares of common stock. The shares were priced at $3.50 per share at-the-market under Nasdaq rules.

H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The medical aesthetic technology company plans to utilize the net proceeds, after deducting placement agent fees and other offering expenses, for general corporate purposes. The offering was conducted through a shelf registration statement on Form S-3 that received SEC effectiveness on November 1, 2024.

Venus Concept (NASDAQ: VERO) has announced a registered direct offering of 328,573 shares of common stock priced at $3.50 per share, expected to raise approximately $1.1 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules.

The closing is anticipated around April 10, 2025, subject to customary conditions. H.C. Wainwright & Co. serves as the exclusive placement agent. The company plans to use the net proceeds for general corporate purposes. The offering is made pursuant to an effective S-3 shelf registration statement previously filed with the SEC.

Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has scheduled the release of its first quarter fiscal year 2025 financial results for Thursday, May 15, 2025, before market opening. The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session.

Interested participants can join via phone using the access code 13753054: domestic callers can dial 877-407-2991, while international callers should use 201-389-0925. A live webcast will be available on the company's investor relations website. A two-week replay will be accessible using the same access code: 877-660-6853 for domestic and 201-612-7415 for international callers.